Page 3 - Vivimed Labs Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vivimed labs ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vivimed Labs Ltd Today - Breaking & Trending Today

Vivimed Labs Ltd Q1FY22 consolidated loss at Rs. 2.33 crore

Vivimed Labs Ltd Q1FY22 consolidated loss at Rs. 2.33 crore
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Vivimed Labs Ltd , Time Zone , Vivimed Labs , நேரம் ஸோந் ,

Vivimed announces the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg

Vivimed announces the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Ramesh Krishnamurthy , Vivimed Labs Limited , Vivimed Labs Ltd , Time Zone , Labs Limited , Specialty Chemicals , Vivimed Hyderabad , ரமேஷ் கிருஷ்ணமூர்த்தி , நேரம் ஸோந் , ஆய்வகங்கள் வரையறுக்கப்பட்டவை , சிறப்பு இரசாயனங்கள் ,

Covid 19 Medicine Favipiravir News: Vivimed Labs Gains On Receiving Government's Approval To Make Favipiravir Tablets

Vivimed Labs Gains On Receiving Government s Approval To Make Favipiravir
Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country.
Updated: May 10, 2021 12:19 pm IST
Shares of the Hyderabad-based drug maker - Vivimed Labs - were locked in a five per cent upper circuit at Rs 28.45 after it received government of India s approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg for Indian market.
Vivimed Labs Limited, a niche specialty chemicals and pharmaceuticals company, announced today, the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed s own brand name Favulous across India, the company said in a press release. ....

Ramesh Krishnamurthy , Health Services , Vivimed Labs , Vivimed Labs Ltd , Favipiravir Tablet , Labs Limited , Director General , ரமேஷ் கிருஷ்ணமூர்த்தி , ஆரோக்கியம் சேவைகள் , ஆய்வகங்கள் வரையறுக்கப்பட்டவை , இயக்குனர் ஜநரல் ,

Vivimed announces the receipt of Government of India approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market

Vivimed announces the receipt of Government of India approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Ramesh Krishnamurthy , Vivimed Labs Limited , Health Services , Vivimed Labs Ltd , Favipiravir Tablet , Time Zone , Labs Limited , Specialty Chemicals , Director General , ரமேஷ் கிருஷ்ணமூர்த்தி , ஆரோக்கியம் சேவைகள் , நேரம் ஸோந் , ஆய்வகங்கள் வரையறுக்கப்பட்டவை , சிறப்பு இரசாயனங்கள் , இயக்குனர் ஜநரல் ,

Approval for Vivimed to manufacture Favipiravir tablets - The Hindu BusinessLine

Approval for Vivimed to manufacture Favipiravir tablets
May 10, 2021
To be used for treatment of mild to moderate cases of Covid-19
Vivimed Labs Limited, a Specialty Chemicals and Pharmaceuticals company, has announced it has received Government of India (Director General of Health Services) approval for manufacture and marketing of Favipiravir tablet of 200 mg & 400 mg under Vivimed’s own brand Favulous across India.
These are used for the treatment of mild to moderate cases of Covid-19. Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.
Favipiravir registered highest sales in April 2021. Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd, informed the BSE: “With huge spike in Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching Favulous at a compe ....

Ramesh Krishnamurthy , Health Services , Vivimed Labs , Vivimed Labs Ltd , Vivimed Labs Limited , Specialty Chemicals , Director General , ரமேஷ் கிருஷ்ணமூர்த்தி , ஆரோக்கியம் சேவைகள் , சிறப்பு இரசாயனங்கள் , இயக்குனர் ஜநரல் ,